logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
P

Peifen Fu

zhejiang university school of medicine
H指数:15
被引数:1,295

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
IF55
2025-02-251
PRE
Chen, Li; Li, Hui; Zhang, Hao; Yang, Huawei; Qian, Jun; Li, Zhihua; Ren, Yu; Wang, Shu; Fu, Peifen; Yang, Hongjian; Liu, Yunjiang; Sun, Jing; Nie, Jianyun; Lei, Ruiwen; Yao, Yongzhong; Zhang, Anqin; Wang, Shouman; Ma, Xiaopeng; Ouyang, Zhong; Yang, Hongwei; Wu, Song-Yang; Cao, Shuo-Wen; Wang, Kun; Jiang, Aimei; Ouyang, Quchang; Pang, Da; Wei, Limin; Zha, Xiaoming; Shen, Yu; Qu, Xiangwen; Wu, Fei; Zhu, Xiaoyu; Wang, Zhonghua; Fan, Lei; Shao, Zhi-Ming
Sentinel lymph node biopsy using dye alone in patients with initially cN1 breast cancer and ycN0 status after neoadjuvant therapy: a multicenter diagnostic trial

使用染料单独进行的哨兵淋巴结活检在初始cN1乳腺癌患者和接受新辅助治疗后ycN0状态的患者中的多中心诊断试验

LANCET REGIONAL HEALTH-WESTERN PACIFIC
IF8.1
2025-02-010
OAAI
Zheng, Ang; Zhang, Lei; Cao, Yu; Zhang, Dian-Long; Ma, Fei; Li, Jian-Yi; Yao, Fan; Ma, Li; Fu, Pei-Fen; Wang, Jia; Nie, Jian-Yun; Xu, Ying-Ying; Guo, Bao-Liang; Jin, Feng; Chen, Bo
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
FUTURE ONCOLOGY
IF2.6
2024-12-040
OAAI
Jiang, Zefei; Ouyang, Quchang; Sun, Tao; Zhang, Qingyuan; Teng, Yuee; Cui, Jiuwei; Wang, Haibo; Yin, Yongmei; Wang, Xiaojia; Zhou, Xin; Wang, Yongsheng; Sun, Gang; Wang, Jingfen; Zhang, Lili; Yang, Jin; Qian, Jun; Yan, Min; Liu, Xinlan; Yi, Tienan; Cheng, Ying; Li, Man; Zang, Aimin; Wang, Shusen; Wang, Chuan; Wu, Xinhong; Cheng, Jing; Li, Hui; Lin, Ying; Geng, Cuizhi; Gu, Kangsheng; Xie, Chunwei; Xiong, Huihua; Wu, Xiaohong; Yang, Junlan; Li, Qingshan; Chen, Yiding; Li, Fanfan; Zhang, Anqin; Zhang, Yongqiang; Wu, Yudong; Nie, Jianyun; Liu, Qiang; Wang, Kun; Mo, Xueli; Chen, Lilin; Pan, Yueyin; Fu, Peifen; Zhang, Helong; Pang, Danmei; Sheng, Yuan; Han, Yunwei; Wang, Hongxia; Cang, Shundong; Luo, Xianming; Yu, Wenbo; Deng, Rong; Yang, Chaoqiang; Keegan, Patricia
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Toripalimab联合nab-紫杉醇治疗转移性或复发性三阴性乳腺癌: 一项随机3期试验

NATURE MEDICINE
IF50
2024-01-0827
PRE
Jiang, Zefei; Ouyang, Quchang; Sun, Tao; Zhang, Qingyuan; Teng, Yuee; Cui, Jiuwei; Wang, Haibo; Yin, Yongmei; Wang, Xiaojia; Zhou, Xin; Wang, Yongsheng; Sun, Gang; Wang, Jingfen; Zhang, Lili; Yang, Jin; Qian, Jun; Yan, Min; Liu, Xinlan; Yi, Tienan; Cheng, Ying; Li, Man; Zang, Aimin; Wang, Shusen; Wang, Chuan; Wu, Xinhong; Cheng, Jing; Li, Hui; Lin, Ying; Geng, Cuizhi; Gu, Kangsheng; Xie, Chunwei; Xiong, Huihua; Wu, Xiaohong; Yang, Junlan; Li, Qingshan; Chen, Yiding; Li, Fanfan; Zhang, Anqin; Zhang, Yongqiang; Wu, Yudong; Nie, Jianyun; Liu, Qiang; Wang, Kun; Mo, Xueli; Chen, Lilin; Pan, Yueyin; Fu, Peifen; Zhang, Helong; Pang, Danmei; Sheng, Yuan; Han, Yunwei; Wang, Hongxia; Cang, Shundong; Luo, Xianming; Yu, Wenbo; Deng, Rong; Yang, Chaoqiang; Keegan, Patricia
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

pyrotinib、曲妥珠单抗和多西他赛新辅助治疗HER2-positive乳腺癌 (PHEDRA): 一项双盲、随机3期试验

BMC MEDICINE
IF8.3
2022-12-2748
OAAI
Wu, Jiong; Jiang, Zefei; Liu, Zhenzhen; Yang, Benlong; Yang, Hongjian; Tang, Jinhai; Wang, Kun; Liu, Yunjiang; Wang, Haibo; Fu, Peifen; Zhang, Shuqun; Liu, Qiang; Wang, Shusen; Huang, Jian; Wang, Chuan; Wang, Shu; Wang, Yongsheng; Zhen, Linlin; Zhu, Xiaoyu; Wu, Fei; Lin, Xiang; Zou, Jianjun
Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study
CANCER RESEARCH
IF16.6
2022-02-150
PRE
He, Min; Yang, Benlong; Wu, Jiong; Liu, Zhenzhen; Yang, Hongjian; Tang, Jinhai; Wang, Kun; Liu, Yunjiang; Wang, Haibo; Fu, Peifen; Zhang, Shuqun; Liu, Qiang; Jiang, Zefei; Wang, Shusen; Huang, Jian; Wang, Chuan; Wang, Shu; Wang, Yongsheng; Zhen, Linlin; Zhu, Xiaoyu; Liu, Shulin; Yan, Ping; Zou, Jianjun
Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study
CANCER RESEARCH
IF16.6
2022-02-150
PRE
Wu, Jiong; Liu, Zhenzhen; Yang, Hongjian; Tang, Jinhai; Wang, Kun; Liu, Yunjiang; Wang, Haibo; Fu, Peifen; Zhang, Shuqun; Liu, Qiang; Jiang, Zefei; Wang, Shusen; Huang, Jian; Wang, Chuan; Wang, Shu; Wang, Yongsheng; Zhen, Linlin; Zhu, Xiaoyu; Wu, Fei; Zhang, Tao; Zou, Jianjun
Proactive diarrhea management improved tolerability of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2+early or locally advanced breast cancer: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study
CANCER RESEARCH
IF16.6
2022-02-150
PRE
Yang, Benlong; Wu, Jiong; Liu, Zhenzhen; Yang, Hongjian; Tang, Jinhai; Wang, Kun; Liu, Yunjiang; Wang, Haibo; Fu, Peifen; Zhang, Shuqun; Liu, Qiang; Jiang, Zefei; Wang, Shusen; Huang, Jian; Wang, Chuan; Wang, Shu; Wang, Yongsheng; Zhen, Linlin; Wu, Fei; Liu, Shulin; Lin, Xiang; Zou, Jianjun
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020
ECLINICALMEDICINE
IF10
2020-09-0146
OAAI
Li, Jianbin; Wang, Haibo; Geng, Cuizhi; Liu, Zhenzhen; Lin, Ying; Nie, Jianyun; Sun, Gang; Ouyang, Quchang; Wang, Xiaojia; Li, Xingrui; Liu, Yinhua; Chen, Qianjun; Fu, Peifen; Yao, Feng; Chen, Jishang; Chen, Yiding; Zhao, Haidong; Yin, Yongmei; Zhang, Jingjie; Chen, Jiayi; Kong, Xiangshun; Cheng, Jing; Zhang, Haiqing; Peng, Shijun; Wang, Geng; Jin, Feng; Liu, Yunjiang; Wu, Gang; Sun, Shengrong; Jiang, Zefei
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial
CANCER RESEARCH
IF16.6
2020-02-151
PRE
Li, Junjie; Yu, Keda; Pang, Da; Wang, Changqin; Jiang, Jun; Yang, Suisheng; Liu, Yunjiang; Fu, Peifen; Sheng, Yuan; Zhang, Guojun; Cao, Yali; He, Qi; Cui, Shude; Wang, Xijing; Ren, Guosheng; Li, Xinzheng; Yu, Shiyou; Liu, Pengxi; Tang, Jinhai; Wang, Ouchen; Fan, Zhimin; Jiang, Guoqin; Zhang, Jin; Shao, Zhimin

研究方向

暂未获取到该数据
K
Kun Wang
H 指数:46论文数:470被引数:7,764
Y
Yunjiang Liu
H 指数:20论文数:96被引数:1,684
Z
Zefei Jiang
H 指数:46论文数:376被引数:1.5万
Y
Yongsheng Wang
H 指数:27论文数:172被引数:2,608
刘
刘强
H 指数:88论文数:942被引数:3.5万
S
Shusen Wang
H 指数:39论文数:237被引数:6,487
刘真真 封面图
刘真真
H 指数:43论文数:474被引数:6,727
朱
朱小玉
H 指数:33论文数:262被引数:4,406
H
Haibo Wang
H 指数:35论文数:293被引数:4,500
S
Shuqun Zhang
H 指数:70论文数:313被引数:2.3万